BCDA
BioCardia, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Neutral
-15/100
Last price
1.06
▼ 0.03 (2.75%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
1.09
Day high
1.11
Day low
1.05
Volume
113.42K
Market cap
$16.05M
P/E (TTM)
—
52W range
0.75 – 1.80
Trailing performance
Returnvs SPY
1W
+2.91%
+1.0%
1M
-1.85%
-3.0%
3M
+9.28%
+4.8%
6M
-10.92%
-29.1%
YTD
-15.20%
-29.4%
1Y
-22.06%
-38.5%
3Y
-83.57%
-165.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on BCDA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
2.71M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 29, 26 | ALTMAN PETER Chief Executive Officer |
BUY | 1.00K | $1.03K | Direct |
| Sep 23, 26 | ALTMAN PETER Chief Executive Officer |
BUY | 1.90K | $2.00K | Direct |
| Sep 3, 26 | ALTMAN PETER Chief Executive Officer |
BUY | 800 | $872 | Direct |
| Aug 17, 26 | ALTMAN PETER Chief Executive Officer |
BUY | 5.40K | $5.02K | Direct |
| Aug 13, 26 | ALTMAN PETER Chief Executive Officer |
BUY | 1.90K | $1.75K | Direct |
| Jul 29, 26 | ALTMAN PETER Chief Executive Officer |
BUY | 5.00K | $3.90K | Direct |
| Jul 17, 26 | ALTMAN PETER Chief Executive Officer |
BUY | 500 | $415 | Direct |
| Jul 15, 26 | ALTMAN PETER Chief Executive Officer |
BUY | 4.30K | $3.75K | Direct |
| Jul 10, 26 | ALTMAN PETER Chief Executive Officer |
BUY | 7.50K | $7.17K | Direct |
| Jul 8, 26 | ALTMAN PETER Chief Executive Officer |
BUY | 5.40K | $5.21K | Direct |
| Jun 29, 26 | GILLIS EDWARD M Officer |
STOCK | 39.52K | $47.42K | Direct |
| Jun 29, 26 | MCCLUNG DAVID Chief Financial Officer |
STOCK | 60.48K | $72.58K | Direct |
| Jun 29, 26 | ALTMAN PETER Chief Executive Officer |
STOCK | 110.63K | $132.75K | Direct |
| Jun 23, 26 | STERTZER SIMON H Director |
BUY | 109.20K | $103.58K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ALTMAN PETER |
Chief Executive Officer | 384.88K | Purchase |
BLANK ANDREW SCOTT |
Director | — | Purchase |
FACTEAU BILL |
Director | 13.12K | Purchase |
GILLIS EDWARD M |
Officer | 71.39K | Stock Award(Grant) |
KRASNO RICHARD M |
Director | 16.27K | Purchase |
MCCLUNG DAVID |
Chief Financial Officer | 137.37K | Stock Award(Grant) |
STERTZER SIMON H |
Director | 823.48K | Purchase |
Fundamentals
Market cap$16.05M
Enterprise value$12.22M
Revenue (TTM)—
Gross profit$-4.19M
EBITDA$-7.38M
Net income$-7.34M
EPS (TTM)$-0.64
Free cash flow$-5.66M
Total cash$4.12M
Total debt$293.00K
Book value / share$0.18
Shares outstanding15.14M
Float12.26M
Short % of float6.51%
Dividend yield0.00%
Beta (5Y)0.62
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.83
PEG ratio—
Price / sales—
Price / book5.89
EV / revenue—
EV / EBITDA-1.66
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-1803.19%
Return on assets-134.97%
Debt / equity10.85
Current ratio2.09
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $58.00K | $477.00K | $1.35M | — | -100.0% |
| Operating revenue | $0 | $58.00K | $477.00K | $1.35M | — | -100.0% |
| Cost of revenue | — | — | — | — | $0 | — |
| Gross profit | — | — | — | — | $1.01M | — |
| Research & development | $4.96M | $4.39M | $7.73M | $8.83M | — | +13.1% |
| Selling, general & admin | $3.32M | $3.67M | $4.39M | $4.42M | — | -9.7% |
| Total operating expense | $8.28M | $8.06M | $12.12M | $13.25M | — | +2.7% |
| Operating income | -$8.28M | -$8.00M | -$11.64M | -$11.90M | — | -3.5% |
| Net interest income | — | — | — | — | $9.00K | — |
| Pre-tax income | -$8.23M | -$7.95M | -$11.57M | -$11.91M | — | -3.5% |
| Net income | -$8.23M | -$7.95M | -$11.57M | -$11.91M | — | -3.5% |
| Net income to common | -$8.23M | -$7.95M | -$11.57M | -$11.91M | — | -3.5% |
| Basic EPS | -1.23 | -2.90 | -8.19 | -10.05 | — | +57.6% |
| Diluted EPS | -1.23 | -2.90 | -8.19 | -10.05 | — | +57.6% |
| EBIT | -$8.28M | -$8.00M | -$11.64M | -$11.90M | — | -3.5% |
| EBITDA | -$8.25M | -$7.93M | -$11.56M | -$11.82M | — | -4.0% |
| Basic shares | 6.67M | 2.74M | 1.41M | 1.18M | — | +143.0% |
| Diluted shares | 6.67M | 2.74M | 1.41M | 1.18M | — | +143.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $2.50M | $2.37M | $1.10M | $7.36M | +5.3% |
| Cash & short-term investments | $2.50M | $2.37M | $1.10M | $7.36M | +5.3% |
| Accounts receivable | $20.00K | $0 | $63.00K | $201.00K | — |
| Total current assets | $2.73M | $2.62M | $1.46M | $7.86M | +4.2% |
| Property, plant & equipment | $510.00K | $931.00K | $1.36M | $1.76M | -45.2% |
| Total assets | $3.41M | $3.72M | $2.99M | $9.79M | -8.4% |
| Total current liabilities | $2.43M | $2.32M | $3.61M | $3.58M | +4.8% |
| Total debt | $528.00K | $951.00K | $1.31M | $1.63M | -44.5% |
| Total liabilities | $2.52M | $2.89M | $4.59M | $4.90M | -12.8% |
| Retained earnings | -$168.35M | -$160.12M | -$152.18M | -$140.60M | -5.1% |
| Shareholder equity | $895.00K | $837.00K | -$1.60M | $4.89M | +6.9% |
| Working capital | $300.00K | $301.00K | -$2.15M | $4.28M | -0.3% |
| Net tangible assets | $895.00K | $837.00K | -$1.60M | $4.89M | +6.9% |
| Shares issued | 10.76M | 4.60M | 1.58M | 1.34M | +133.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$8.23M | -$7.95M | -$11.57M | -$11.91M | -3.5% |
| Depreciation & amortisation | $24.00K | $67.00K | $84.00K | $82.00K | -64.2% |
| Stock-based compensation | $430.00K | $741.00K | $1.03M | $1.18M | -42.0% |
| Change in working capital | -$143.00K | -$1.20M | $129.00K | -$214.00K | +88.0% |
| Operating cash flow | -$7.44M | -$7.89M | -$9.97M | -$10.56M | +5.7% |
| Capital expenditure | -$7.00K | -$6.00K | -$12.00K | -$70.00K | -16.7% |
| Investing cash flow | -$7.00K | -$6.00K | -$12.00K | -$70.00K | -16.7% |
| Financing cash flow | $7.57M | $9.16M | $3.73M | $5.12M | -17.4% |
| Free cash flow | -$7.44M | -$7.89M | -$9.99M | -$10.63M | +5.7% |
| End cash position | $2.50M | $2.37M | $1.10M | $7.36M | +5.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | — | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | — | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | — | $1.24M | $1.13M | $936.00K | $1.37M | $1.53M | — |
| Selling, general & admin | — | $1.03M | $885.00K | $552.00K | $683.00K | $1.20M | — |
| Total operating expense | — | $2.27M | $2.01M | $1.49M | $2.05M | $2.73M | — |
| Operating income | — | -$2.27M | -$2.01M | -$1.49M | -$2.05M | -$2.73M | — |
| Pre-tax income | — | -$2.26M | -$1.98M | -$1.48M | -$2.05M | -$2.71M | — |
| Net income | — | -$2.26M | -$1.98M | -$1.48M | -$2.05M | -$2.71M | — |
| Net income to common | — | -$2.26M | -$1.98M | -$1.48M | -$2.05M | -$2.71M | — |
| Basic EPS | -0.13 | -0.21 | — | -0.24 | -0.40 | -0.59 | +38.1% |
| Diluted EPS | -0.13 | -0.21 | — | -0.24 | -0.40 | -0.59 | +38.1% |
| EBIT | — | -$2.27M | -$2.01M | -$1.49M | -$2.05M | -$2.73M | — |
| EBITDA | — | -$2.26M | -$2.01M | -$1.48M | -$2.05M | -$2.71M | — |
| Basic shares | 12.09M | 10.81M | — | 6.28M | 5.06M | 4.64M | +11.8% |
| Diluted shares | 12.09M | 10.81M | — | 6.28M | 5.06M | 4.64M | +11.8% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $951.00K | $2.50M | $5.29M | $980.00K | $949.00K | -61.9% |
| Cash & short-term investments | $951.00K | $2.50M | $5.29M | $980.00K | $949.00K | -61.9% |
| Accounts receivable | $20.00K | $20.00K | — | $10.00K | — | 0.0% |
| Total current assets | $1.14M | $2.73M | $5.37M | $1.20M | $1.17M | -58.3% |
| Property, plant & equipment | $401.00K | $510.00K | $612.00K | $719.00K | $822.00K | -21.4% |
| Total assets | $1.71M | $3.41M | $6.15M | $2.09M | $2.17M | -49.8% |
| Total current liabilities | $2.78M | $2.43M | $3.31M | $3.64M | $3.23M | +14.2% |
| Total debt | $412.00K | $528.00K | $638.00K | $745.00K | $850.00K | -22.0% |
| Total liabilities | $2.78M | $2.52M | $3.52M | $3.98M | $3.69M | +10.3% |
| Retained earnings | -$170.61M | -$168.35M | -$166.37M | -$164.88M | -$162.83M | -1.3% |
| Shareholder equity | -$1.07M | $895.00K | $2.63M | -$1.89M | -$1.52M | -219.1% |
| Working capital | -$1.64M | $300.00K | $2.06M | -$2.44M | -$2.06M | -646.0% |
| Net tangible assets | -$1.07M | $895.00K | $2.63M | -$1.89M | -$1.52M | -219.1% |
| Shares issued | 10.94M | 10.76M | 10.61M | 5.50M | 4.68M | +1.7% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$2.26M | -$1.98M | -$1.48M | -$2.05M | -$2.71M | -13.9% |
| Depreciation & amortisation | $3.00K | $3.00K | $4.00K | $5.00K | $12.00K | 0.0% |
| Stock-based compensation | $113.00K | $85.00K | $77.00K | $98.00K | $170.00K | +32.9% |
| Change in working capital | $363.00K | -$783.00K | -$373.00K | $222.00K | $791.00K | +146.4% |
| Operating cash flow | -$1.66M | -$2.50M | -$1.67M | -$1.65M | -$1.62M | +33.6% |
| Capital expenditure | -$3.00K | -$6.00K | — | — | — | +50.0% |
| Investing cash flow | -$3.00K | -$6.00K | $0 | -$1.00K | $0 | +50.0% |
| Financing cash flow | $117.00K | -$288.00K | $5.98M | $1.68M | $196.00K | +140.6% |
| Free cash flow | -$1.66M | -$2.50M | -$1.67M | -$1.65M | -$1.62M | +33.6% |
| End cash position | $951.00K | $2.50M | $5.29M | $980.00K | $949.00K | -61.9% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.19 | -0.13 | +31.6% |
| Mar 2026 | -0.17 | -0.21 | -23.5% |
| Dec 2025 | -0.20 | -0.06 | +70.0% |
| Sep 2025 | -0.25 | -0.24 | +4.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.15 | 1 | $0 | 0.0% |
| Next quarter | -0.21 | 1 | $0 | 0.0% |
| Current year | -0.71 | 1 | $0 | 0.0% |
| Next year | -0.58 | 1 | $0 | 0.0% |
Analyst targets & ownership
Mean target$15.50
High target$25.00
Low target$6.00
Implied upside1362.26%
Analyst count2
ConsensusNONE
Strong buy / Buy0 / 2
Hold0
Sell / Strong sell0 / 0
Held by insiders17.92%
Held by institutions14.79%
Institutions holding24
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.05
+1.34% from price
SMA 20
1.09
-2.84% from price
SMA 50
1.03
+2.95% from price
SMA 100
0.99
+6.95% from price
SMA 200
1.11
-4.24% from price
EMA 12
1.06
-0.18% from price
EMA 26
1.07
-0.64% from price
EMA 50
1.05
+0.99% from price
RSI (14)
49.2
Neutral
MACD (12,26,9)
-0.00
Hist -0.01
ATR (14)
0.07
6.81% of price
Realised vol 30D
64.8%
Annualised
Bollinger upper
1.22
20, 2σ
Bollinger lower
0.96
20, 2σ
50 / 200 cross
Death
1.03 vs 1.11
Trend bias
Below 200
-4.24%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.53
Less volatile than market
Correlation to SPY
0.10
Largely independent
Realised vol 30D
64.8%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-50.6%
Peak to trough
Max drawdown 5Y
-98.3%
Peak to trough
ATR 14
0.07
6.81% of price
Beta (reported)
0.62
5Y monthly, from filing
Short interest
Shares short
863.66K
Prior 1.03M
Change vs prior
-16.1%
Shorts covering
% of float
6.51%
Normal
% of shares out
5.70%
Against total outstanding
Days to cover
4.2
Liquid
Float
12.26M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 24, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 9, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 22, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Dec 18, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 14, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Oct 28, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 21, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 16, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 26, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 29, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 14, 23 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Oct 11, 23 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateJun 6, 2019
Last split1:15
Split dateMay 30, 2024
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-10-01
Corporate Changes & Voting Matters
8-K · 2026-09-23
Corporate Changes & Voting Matters
8-K · 2026-09-21
Corporate Changes & Voting Matters
8-K · 2026-09-10
Corporate Changes & Voting Matters
8-K · 2026-08-24
Corporate Changes & Voting Matters
8-K · 2026-08-21
Periodic Financial Reports
10-Q · 2026-08-12
Corporate Changes & Voting Matters
8-K · 2026-06-18
Headlines
BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter
GlobeNewswire · 6d ago
BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission
GlobeNewswire · 14d ago
BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · 27d ago
BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval
GlobeNewswire · 44d ago
BioCardia (BCDA) Q2 2026 Earnings Call Transcript
Motley Fool · 48d ago
BioCardia Inc (BCDA) (Q2 2026) Earnings Call Highlights: Regulatory Wins in Japan and US ...
GuruFocus.com · 55d ago
BioCardia, Inc. Q2 2026 Earnings Call Summary
Moby · 55d ago
BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results
GlobeNewswire · 56d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.